Following the FSA's 24 February 2026 update, UK employers must refresh CBD policies to address THC contamination, microdosing and drug‑testing challenges. This article summarises testing methods and costs, data‑protection obligations, the need for Certificates of Analysis (COAs), and pragmatic policy changes HR teams should adopt now.

Major UK retailers are introducing premium CBD serums, microdose topicals and pharmacy‑grade patches in 2026. This article explains the latest 2023–2026 clinical evidence, post‑Brexit safety expectations, product innovation and sustainability credentials UK shoppers should look for.

This 2026 UK guide explains how CBD fits into post‑workout recovery for athletes and gym‑goers while navigating WADA/UKAD rules. Learn the difference between topical balms and oral oils, why batch testing and COAs matter, and practical steps to reduce anti‑doping risk.